Serum level of midregional fragment of proadrenomedullin as an early sepsis marker in severely neutropenic patients with hematologic malignancies

2019 ◽  
Vol 44 (2) ◽  
pp. 118
Author(s):  
MaggieM Fawzi ◽  
AlaaA Omran ◽  
BotheinaA Masood
2016 ◽  
Vol 37 (7) ◽  
pp. 845-851 ◽  
Author(s):  
Marie-Paule Fernandez-Gerlinger ◽  
Anne-Sophie Jannot ◽  
Sophie Rigaudeau ◽  
Juliette Lambert ◽  
Odile Eloy ◽  
...  

OBJECTIVEInvasive aspergillosis (IA) is a rare but severe infection caused by Aspergillus spp. that often develops in immunocompromised patients. Lethality remains high in this population. Therefore, preventive strategies are of key importance. The impact of a mobile air decontamination system (Plasmair, AirInSpace, Montigny-le-Bretonneux, France) on the incidence of IA in neutropenic patients was evaluated in this study.DESIGNRetrospective cohort studyMETHODSPatients with chemotherapy-induced neutropenia lasting 7 days or more were included over a 2-year period. Cases of IA were confirmed using the revised European Organization for Research and Treatment of Cancer (EORTC) criteria. We took advantage of a partial installation of Plasmair systems in the hematology intensive care unit during this period to compare patients treated in Plasmair-equipped versus non-equipped rooms. Patients were assigned to Plasmair-equipped or non-equipped rooms depending only on bed availability. Differences in IA incidence in both groups were compared using Fisher’s exact test, and a multivariate analysis was performed to take into account potential confounding factors.RESULTSData from 156 evaluable patients were available. Both groups were homogenous in terms of age, gender, hematological diagnosis, duration of neutropenia, and prophylaxis. A total of 11 cases of probable IA were diagnosed: 10 in patients in non-equipped rooms and only 1 patient in a Plasmair-equipped room. The odds of developing IA were much lower for patients hospitalized in Plasmair-equipped rooms than for patients in non-equipped rooms (P=.02; odds ratio [OR] =0.11; 95% confidence interval [CI], 0.00–0.84).CONCLUSIONIn this study, Plasmair demonstrated a major impact in reducing the incidence of IA in neutropenic patients with hematologic malignancies.Infect Control Hosp Epidemiol 2016;37:845–851


Leukemia ◽  
2005 ◽  
Vol 19 (4) ◽  
pp. 545-550 ◽  
Author(s):  
K Mühlemann ◽  
C Wenger ◽  
R Zenhäusern ◽  
M G Täuber

Pharmaceutics ◽  
2020 ◽  
Vol 12 (9) ◽  
pp. 785
Author(s):  
Pier Giorgio Cojutti ◽  
Anna Candoni ◽  
Davide Lazzarotto ◽  
Carla Filì ◽  
Maria Zannier ◽  
...  

A population pharmacokinetic analysis of continuous infusion (CI) meropenem was conducted in a prospective cohort of febrile neutropenic (FN) patients with hematologic malignancies. A non-parametric approach with Pmetrics was used for pharmacokinetic analysis and covariate evaluation. Monte Carlo simulations were performed for identifying the most appropriate dosages for empirical treatment against common Enterobacterales and P. aeruginosa. The probability of target attainment (PTA) of steady-state meropenem concentration (Css)-to-minimum inhibitory concentration (MIC) ratio (Css/MIC) ≥1 and ≥4 at the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoint of 2 mg/L were calculated. Cumulative fraction of response (CFR) against Enterobacterales and P. aeruginosa were assessed as well. PTAs and CFRs ≥ 90% were considered optimal. A total of 61 patients with 178 meropenem Css were included. Creatinine clearance (CLCR) was the only covariate associated with meropenem clearance. Monte Carlo simulations showed that dosages of meropenem ranging between 1 g q8h and 1.25 g q6h by CI may grant optimal PTAs of Css/MIC ≥4 at the EUCAST clinical breakpoint. Optimal CFRs may be granted with these dosages against the Enterobacterales at Css/MIC ≥ 4 and against P. aeruginosa at Css/MIC ≥ 1. When dealing against P. aeruginosa at Css/MIC ≥ 4, only a dosage of 1.5 g q6h by CI may grant quasi-optimal CFR (around 80–87%). In conclusion, our findings suggest that dosages of meropenem ranging between 1 g q8h and 1.25 g q6h by CI may maximize empirical treatment against Enterobacterales and P. aeruginosa among FN patients with hematologic malignancies having different degree of renal function.


2004 ◽  
Vol 2 (5) ◽  
pp. 445-451 ◽  
Author(s):  
Michael Kleinberg

Preventing bacterial infections by prescribing prophylactic antibiotics is seen by many as an important strategy for decreasing infectious mortality in the most profoundly immunosuppressed patients with hematologic malignancies. Comparative studies show consistently that neutropenic patients treated with prophylactic fluoroquinolone antibiotics develop fewer bacteremias than patients treated with placebo or less-potent antibacterials. However, these same studies fail to show increased survival rates in fluoroquinolone-treated patients. This repeated observation is the basis for the continued controversy concerning universal antibacterial prophylaxis of neutropenic patients, namely, the inability to translate the observed reduction in culture-proven bacterial infections with prophylaxis into improved clinical outcomes. The answer to this controversy lies in the effectiveness of empiric antibacterial therapy in response to neutropenic fevers. Mortality from bacterial infections is 1% or less for patients enrolled in empiric treatment trials who do not receive prophylactic antibacterials. Therefore, routine fluoroquinolone prophylaxis offers essentially no potential survival benefit to neutropenic patients with hematologic malignancies. In fact, the increasing potential for fluoroquinolones to select for resistant bacterial pathogens should give pause to the practice of routine prophylaxis of neutropenic patients.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3797-3797
Author(s):  
Laura Kyle Brett ◽  
Gerald R. Donowitz ◽  
Heather Cox ◽  
Gina Petroni ◽  
John Densmore

Abstract Abstract 3797 Introduction and Goals. Clostridium difficile infection (CDI) is increasing in frequency and severity. Risk factors for severity of illness and treatment recommendations for patients with concurrent aggressive hematologic malignancies have not been investigated, despite data showing that this population experiences a high rate of CDI. The goal of this study was to assess mortality associated from CDI as well as risk factors for severe CDI in a population of patients with acute hematologic malignancies. Methods. Ninety-three cases of CDI among 78 patients with active acute leukemia or aggressive lymphoma at the University of Virginia (UVa) Health System from 2004–2009 were studied retrospectively. Rates of all-cause mortality, attributable mortality secondary to CDI (defined as CDI with at least one of the following: active diarrhea, toxic megacolon, or pseudomembranes on colonoscopy at time of death), and a composite outcome (defined as at least one of the following: attributable mortality, ICU stay from CDI, pseudomembranous colitis, toxic megacolon, or colectomy) were assessed as adverse outcomes. The following potential risk factors for severe CDI were investigated, adjusting for age: onset and duration of neutropenia, exposure to high dose cytarabine, number of antimicrobials given, exposure to fluoroquinolone prophylaxis for neutropenic fever, and a designation of severe CDI as previously described (at least two of the following: white blood count >15,000 cells/mL, age >60 years, albumin <2.5 g/dL, temperature >38.3° C, or one of the following: ICU stay or pseudomembranous colitis). Results. All-cause mortality was 21.7%. CDI-attributable mortality was 14.1%. The rate of the composite outcome was 20.3%. All-cause mortality was higher in patients with leukemia and lymphoma than for all other patients hospitalized at this institution with CDI in 2008 (12.5% all-cause mortality, 76/610, p=0.015, 95% CI [13.2, 32.6]). Duration of neutropenic episode >14 days and neutropenia at diagnosis of CDI were associated with increased risk of attributable mortality (OR 3.12, 95% CI [0.82, 11.92], p=0.09; OR 3.39, 95% CI [0.57, 20.05], p=0.11). Cumulative duration of neutropenia >21 days was not associated with increased risk in adverse outcomes. Designation of severe CDI predicted an increase in all-cause mortality (OR 6.7, 95% CI [2.1, 21.5], p <0.001), attributable mortality (OR 11.5, 95% CI [2.3, 57.5], p <0.001), and the composite outcome, (OR 19.3, 95% CI [5.5, 74.7], p <0.001). Fluoroquinolone prophylaxis for neutropenic fever, high dose cytarabine, induction chemotherapy, or receipt of more than 2 concurrent antimicrobials were not associated with increased risk of all-cause mortality, attributable mortality or the composite outcome. Discussion. Patients with acute hematologic malignancies and concurrent CDI were at increased risk of all-cause and CDI-attributable mortality compared with similar data from UVa of all hospitalized patients. Prolonged neutropenia at time of CDI diagnosis was associated with an increased risk of CDI-attributable mortality, although this result was not statistically significant. Established criteria for diagnosing severe CDI were helpful at predicting poor outcomes in this population. Seven of the 10 neutropenic patients who died in this study did not receive oral vancomycin. Neutropenic patients with CDI may benefit from initial treatment with oral vancomycin instead of metronidazole, especially if other criteria for severe illness are present. Future research may assess effectiveness of oral vancomycin as initial treatment for CDI in neutropenic patients. Disclosures: No relevant conflicts of interest to declare.


1999 ◽  
Vol 37 (6) ◽  
pp. 1876-1880 ◽  
Author(s):  
H. Wisplinghoff ◽  
R. R. Reinert ◽  
O. Cornely ◽  
H. Seifert

From January 1995 to May 1998, 57 episodes of bacteremia due to viridans group streptococci were identified in 50 febrile neutropenic patients with hematologic malignancies. Four patients experienced two separate episodes of streptococcal bacteremia, and one patient had four separate episodes of streptococcal bacteremia. Strains were identified to species level as Streptococcus mitis (n= 37), Streptococcus oralis (n = 19), andStreptococcus salivarius (n = 1). Epidemiologic relatedness of these strains was studied by using PCR-based fingerprinting with M13 and ERIC-2 primers and pulsed-field gel electrophoresis with restriction enzyme SmaI. All strains that were isolated from different patients exhibited unique fingerprint patterns, thus suggesting that viridans group streptococcal bacteremia usually derives from an endogenous source. Cross-transmission of strains between patients could not be established. Four S. mitis isolates recovered during four separate bacteremic episodes in a single patient had identical fingerprint patterns. Susceptibility testing was carried out by broth microdilution technique according to National Committee for Clinical Laboratory Standards guidelines. The MICs at which 90% of the isolates are inhibited were (in milligrams per liter) as follows: 0.5 (penicillin), 0.5 (amoxicillin), 0.25 (cefotaxime), 2 (chloramphenicol), 4 (erythromycin), 0.5 (clindamycin), ≥32 (tetracycline), ≥32 (trimethoprim-sulfamethoxazole), 4 (ciprofloxacin), 0.5 (sparfloxacin), 0.5 (vancomycin), 0.25 (teicoplanin), and 1 (quinupristin-dalfopristin). High-level penicillin resistance (MIC, ≥4 mg/liter) was found in one isolate only, but intermediate penicillin resistance was noted in 11 isolates (19%). Resistance rates to other drugs were as follows: 7% (amoxicillin), 4% (cefotaxime), 4% (chloramphenicol), 32% (erythromycin), 9% (clindamycin), 39% (tetracycline), 68% (trimethoprim-sulfamethoxazole), 23% (ciprofloxacin), 0% (sparfloxacin), 0% (vancomycin), 0% (teicoplanin), and 0% (quinupristin-dalfopristin).


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2959-2959
Author(s):  
Shannon Mitchell Cohn ◽  
Hanumantha R. Pokala ◽  
David Leonard ◽  
Tamra Slone ◽  
Martha M. Stegner ◽  
...  

Abstract Infections with invasive molds are an important cause of morbidity and mortality with published mortality rates of 21-48% among pediatric cancer patients infected by these organisms. Diagnosing invasive fungal infections is difficult because signs and symptoms are non-specific, and delays in diagnosis limit successful debridement of infected tissues. Despite this, there are no uniform guidelines for the diagnosis of invasive fungal infections. The deaths of three teens, at our institution, with leukemia and widespread mold, lead to the creation of a screening protocol for invasive fungal infection in November 2006. Neutropenic patients with persistent fever at 5 days or recurrent fever after defervescing were evaluated with a non-contrast computed tomography (CT) of the chest, abdominal ultrasound, and nasal endoscopy, performed at the bedside, by an otorhinolaryngologist. Initially the screen included CT of the abdomen, but the proclivity of mold for solid organ involvement supported the use of ultrasound as a screening tool. Additional studies were obtained as clinically indicated. To determine the impact of this screening protocol on mortality associated with invasive mold, we performed a retrospective chart review of patients receiving intensive therapy for hematologic malignancies from 2004-2011 who were diagnosed as having proven, probable, or possible invasive mold (candida excluded) infections (N=52) using the European Organization for Research and Treatment of Cancer and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) criteria. Of the 20 mold infections in the pre-protocol group, 14 were classified as proven, 6 as possible. Among the 32 infections in the post-protocol group, 22 were proven, 4 probable, and 6 possible. Organisms included Aspergillus, Bipolaris, Curvalaria, Exserohilum, Fusarium, Rhizopus, and Scedosporium. Clinically indicated evaluations among the 20 patients in the pre-protocol group included, 16 chest CTs, 20 abdominal CTs or ultrasounds, and 7 underwent evaluation of their sinuses by direct nasal endoscopy. The lungs were the most common site of infection, with involvement detected in 15/20 patients (75%). Five patients (25%) had sinus involvement; in 1 patient this was the only site of disease. All 5 were symptomatic with rhinorrhea, congestion, facial pain, or facial numbness. Of the 32 patients in the post-protocol group, 30 had chest CTs, 32 had abdominal imaging (5 CT, 27 ultrasound), and 31 had direct nasal endoscopy. One patient did not have an ENT evaluation or chest CT because fungal disease was only detected post-mortem, and in 1 patient, cardiovascular instability precluded CT imaging. The lungs were again the most common site affected, with fungal pneumonia seen in 23/32 patients (72%). Fourteen patients (44%) had sinus involvement; in 4 patients this was the only site of disease. Nine patients with sinus involvement had no nasal symptoms or findings on routine physical exam. Mortality specifically associated with invasive mold infection decreased significantly after initiation of the screening protocol. Before implementing the screening protocol, 8/20 patients (40%) who developed invasive mold infections died from the infection; afterward 4/32 (12.5%), (Fisher's exact p=0.04). Prior to routine evaluation of the sinuses by direct nasal endoscopy, 5/20 patients with mold infections had demonstrable disease in the sinuses and all had symptoms referable to sinus disease prior to evaluation. Once direct nasal endoscopy was implemented as part of the screening protocol, 14/32 patients with invasive mold infection were found to have sinus disease; 9 had no symptoms other than fever. Age, gender, race and length of hospital stay did not differ significantly before and after implementing the screening protocol. Before implementation, 8/20 patients (40%) died from all causes; afterward 6/32 (19%), (Fisher's exact p=0.12). A screening protocol for the evaluation of neutropenic patients with persistent or recurrent fever led to early detection of invasive fungal infections in patients with hematologic malignancies and a significant decrease in infection associated mortality. Non-invasive, direct nasal endoscopy, performed at the bedside, is an effective tool for diagnosis of invasive fungal sinusitis and often detects fungal sinusitis before specific symptoms develop. Disclosures: No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document